Virtual Specialty Care Has Time. Will We Use It Wisely?
The specialty access and capacity crisis demands more than incremental fixes. It requires expanding virtual access and fundamentally rethinking how specialty care can be delivered.
The 340B Program’s New Rebate Pilot Won’t Fix Its Problems
The 340B Drug Pricing Program was designed to help safety net providers serve low-income patients, but it has since ballooned into a multibillion-dollar system dominated by large health systems — with a major lack of transparency about how savings are used to benefit patients. As HRSA launches a new rebate-based model meant to boost oversight, experts warned that it could instead burden smaller providers and fail to address the program’s deeper flaws.
Beyond Analytics: How Sellers Dorsey is Hard-Coding Value into Medicaid Policy [Video]
How to turn analytics into actual policy outcomes.
HRSA Commits $52M to Health Centers Supporting People Leaving Incarceration
The Health Resources and Services Administration is making a $52 million investment in 54 health centers to support the health needs of those leaving incarceration.
Johnson & Johnson Takes the 340B Drug Rebate Fight to Federal Court
Johnson & Johnson is suing the federal agencies overseeing the 340B program that makes discounted medicines more accessible to uninsured and underserved patients. J&J contends the Health Resources Services Administration can’t legally oppose its plan to implement a new rebate plan for certain 340B drugs.
J&J Backs Down From 340B Rebates, But Maintains They’re ‘Legally Permissible’ Per Statute
Johnson & Johnson stopped short of implementing its proposal to alter the way two drugs are paid for under the 340B drug discount program, but the drugmaker made it clear it still wants changes. In other recent regulatory news, we have drug approvals, clinical holds, and one product withdrawal.
J&J’s Change to 340B Discounts is “Inconsistent” with Statute, HRSA Says
Johnson & Johnson announced last week a major change in the way it offers 340B pricing for two medications. The change is "inconsistent" with the 340B statute, according to HRSA.
presented by
Inside an Automated Healthcare Practice: Redesigning Care Around People, Not Paperwork
By reducing administrative burden and redesigning workflows around human needs, it creates space for what matters most: connection between clinicians and patients.
How Covered Entities and Pharma Companies Can Better Collaborate on Drug Discount Programs
Three things drug manufacturers and CEs can do to build trust and enable effective collaboration
Feds expected to scrutinize Covid-era payments to providers
Hospitals, clinics, nursing homes and other providers collected billions in government aid during the pandemic. Federal auditors may soon come knocking to ensure the money was spent correctly.
In fight over drug discounts, HHS lawyer sides with hospitals
Prominent drug companies have said they want to curb waste and abuse in the 340B Drug Pricing Program. But the top lawyer at HHS is echoing the criticism hospitals have been leveling against the drug companies over access to the program.
Hospitals sue drug companies over discount program
The lawsuit follows action by at least a half-dozen drug companies to rein in what they see as waste and abuse in the program, overseen by the Department of Health and Human Services. Meanwhile, the Hospital plaintiffs have a potentially powerful ally in the person picked to head the department under the incoming Biden administration.
The Power Behind Enterprise EHR Software for Large Healthcare Systems
Enterprise EHR boosts scalability, interoperability, and governance for large healthcare systems.